The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era

Clinical Trials

Volumn 3, Issue 2, 2006, Pages 119-132

  Mocroft, A ^a   Neaton, J ^b   Bebchuk, J ^b   Staszewski, S ^c   Antunes, F ^d   Knysz, B ^e   Law, M ^f   Phillips, A N ^a   Lundgren, J D ^g  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MULTICENTER STUDIES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33744796788     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1191/1740774506cn138oa     Document Type: Article

References (22)

1. Fischl MA, Richman D, Grieco MH et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-91.
2. Hammer SM, Squires KE, Hughes MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 1997; 337: 725-33.
3. Cameron DW, Heath-Chiozzi M, Danner S et al. Randomised placebo controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998; 351: 543-49.
4. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-30.
5. Mocroft A, Ledergerber B, Katlama C et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22-29.
6. Staszewski S, Moralis-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999; 341: 1865-73.
7. Gullick RM, Ribaudo HJ, Shikurma CM et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the intitial treatment of HIV-1 infection. N Engl J Med 2004; 350: 1850-61.
8. Phillips AN, Lee CA, Elford J et al. Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991; 337: 389-92.
9. Mellors JW, Rinaldo CR, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
10. Emery S, Abrams DI, Cooper DA et al. The evaluation of subcutaneous proleukin (interleukin-2) in a randomised international trial: rationale, design and methods of ESPRIT. Cont Clin Trials 2002; 23: 198-220.
11. Centers for Disease Control. 1993 revised calssification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41: 1-17.
12. 6/L CD4 cell counts. JAMA 2000; 284: 2193-202.
13. PL Canner, M Halperin. Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary; drug project research group. Circulation 1981; 63: 1342-50.
14. Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe; 1994-1998: The EuroSIDA study. Lancet 2000; 356: 291-96.
15. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
16. Carpenter CCJ, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection in 1998: Updated recomendations of the International AIDS Society-USA panel. JAMA 1998; 280: 78-86.
17. Centers for Disease Control. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents: recommendations of the panel on clinical practises for treatment of HIV. MMWR 2002; 51(RR-7).
18. Madge S, Mocroft A, Wilson D et al. Participation in clinical trials amongst patients infected with HIV 1 in a single treatment centre over 12 years. HIV Medicine 2000; 1: 212-18.
19. Gifford AL, Cunningham WE, Heslin KC et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med 2002; 346: 1373-82.
20. Ederer F, Church TR, Mandel JS. Sample sizes for prevention trials have been too small. Am J Epidemiol 1993; 137: 787-96.
21. Weber R, Friis Moller N, Sabin C et al. HIV and non-HIV related deaths and their relationship to immunodeficiency: The D:A:D study. 12th Conference on Retroviruses and Opportunistic Infections, Feb 22-25, 2005, San Francisco, USA. Abstract 595.
22. Mocroft A, Soriano V, Rockstroh J et al. Evidence for an increase in the death rate from liver-related disease in patients with HIV. AIDS 2005; 19: 2117-25.